2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Lung Neoplasms
2
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasm, Residual
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Hairy Cell
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Ependymoma
1
Carcinoma, Small Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma in Situ
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms
1
Interventions
Rituximab
344
Cyclophosphamide
317
fludarabine phosphate
142
Etoposide
139
Peripheral Blood Stem Cell Transplantation
124
fludarabine
112
Filgrastim
112
Mycophenolic Acid
98
Melphalan
98
Whole-Body Irradiation
90
Vincristine
90
Busulfan
87
Cytarabine
85
Doxorubicin
79
Cyclosporine
76
Tacrolimus
75
Radiotherapy
75
Prednisone
73
Bendamustine Hydrochloride
72
Granulocyte Colony-Stimulating Factor
66
Methotrexate
65
Antilymphocyte Serum
56
Carmustine
54
Dexamethasone
50
Gemcitabine
48
Lenalidomide
46
Bortezomib
43
venetoclax
41
ibritumomab tiuxetan
37
obinutuzumab
36
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
Histamine Antagonists
×
Clear all
NCT00719472
2017-05-15
RATE
Genentech, Inc.
Phase 3
Completed
451 enrolled
11 charts